Rhabdomyosarcoma

Oncology of Infancy and Childhood: Expert Consult - Online and Print

Volumn , Issue , 2009, Pages 743-781

  Barr, Frederic G ^a,b   Womer, Richard B ^a,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85158955201     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-3431-5.00019-4     Document Type: Chapter

References (324)

1. DM Parham and DA Ellison (2006) Rhabdomyosarcomas in adults and children: an update. Arch Pathol Lab Med 130 1454-1465
2. SJ Qualman, CM Coffin, WA Newton, et al. (1998) Intergroup Rhabdomyosarcoma Study: update for pathologists. Pediatr Dev Pathol 1 550-561
3. JE Garber and K Offit (2005) Hereditary cancer predisposition syndromes. J Clin Oncol 23 276-292
4. FP Li (1969) Rhabdomyosarcoma in children: epidemiologic study and identification of a familial cancer syndrome. J Natl Cancer Inst 43 1365-1373
5. JM Birch, AL Hartley, V Blair, et al. (1990) Cancer in the families of children with soft tissue sarcoma. Cancer 66 2239-2248
6. D Malkin, FP Li, LC Strong, et al. (1990) Germline p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250 1233-1238. (comment)
7. JM Varley, G McGown, M Thorncroft, et al. (1997) Germ-line mutations of tp53 in Li-Fraumeni families: an extended study of 39 families. Cancer Res 57 3245-3252
8. Z Sedlacek, R Kodet, E Seemanova, et al. (1998) Two Li-Fraumeni syndrome families with novel germline p53 mutations: loss of the wild-type p53 allele in only 50% of tumours. Br J Cancer 77 1034-1039
9. D Malkin, S Chilton-MacNeill, LA Meister, et al. (2001) Tissue-specific expression of SV40 in tumors associated with the Li-Fraumeni syndrome. Oncogene 20 4441-4449
10. AJ Knudson (1971) Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A 68 820-823
11. RS Cornelis, M van Vliet, MJ van de Vijver, et al. (1997) Three germline mutations in the tp53 gene. Hum Mutat 9 157-163
12. S Avigad, D Peleg, D Barel, et al. (2004) Prenatal diagnosis in Li-Fraumeni syndrome. J Pediatr Hematol Oncol 26 541-545
13. CM Khayat and DL Johnston (2004) Rhabdomyosarcoma, osteosarcoma, and adrenocortical carcinoma in a child with a germline p53 mutation. Pediatr Blood Cancer 43 683-686
14. ME Cavalier, MM Davis and JM Croop (2005) Germline p53 mutation presenting as synchronous tumors. J Pediatr Hematol Oncol 27 441-443
15. L Diller, E Sexsmith, A Gottlieb, et al. (1995) Germline p53 mutations are frequently detected in young children with rhabdomyosarcoma. J Clin Invest 95 1606-1611
16. DW Bell, JM Varley, TE Szydlo, et al. (1999) Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 286 2528-2531
17. SS Donaldson, PR Egbert, I Newsham and WK Cavenee (1997) Retinoblastoma. PA Pizzo, DG Poplack,(Eds) Principles and Practice of Pediatric Oncology 3rd ed Philadelphia: Lippincott-Raven 699-715
18. RA Kleinerman, MA Tucker, DH Abramson, et al. (2007) Risk of soft tissue sarcomas by individual subtype in survivors of hereditary retinoblastoma. J Natl Cancer Inst 99 24-31
19. T Hasegawa, Y Matsuno, T Niki, et al. (1998) Second primary rhabdomyosarcomas in patients with bilateral retinoblastoma: a clinicopathologic and immunohistochemical study. Am J Surg Pathol 22 1351-1360
20. TN Basu, DH Gutmann, JA Fletcher, et al. (1992) Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature 356 713-715
21. GF Xu, P O’Connell, D Viskochil, et al. (1990) The neurofibromatosis type 1 gene encodes a protein related to gap. Cell 62 599-608
22. SA Rasmussen and JM Friedman (2000) NF1 gene and neurofibromatosis 1. Am J Epidemiol 151 33-40
23. SE Plon and LE Peterson (1997) Childhood cancer, heredity, and the environment. P Pizzo, D Poplack,(Eds) Principles and Practice of Pediatric Oncology 3rd ed Philadelphia: Lippincott-Raven 11-36
24. EA McKeen, J Bodurtha, AT Meadows, et al. (1978) Rhabdomyosarcoma complicating multiple neurofibromatosis. J Pediatr 93 992-993
25. P Yang, S Grufferman, MJ Khoury, et al. (1995) Association of childhood rhabdomyosarcoma with neurofibromatosis type I and birth defects. Genet Epidemiol 12 467-474
26. I Matsui, M Tanimura, N Kobayashi, et al. (1993) Neurofibromatosis type 1 and childhood cancer. Cancer 72 2746-2754
27. L Sung, JR Anderson, C Arndt, et al. (2004) Neurofibromatosis in children with rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study IV. J Pediatr 144 666-668
28. RC Hennekam (2003) Costello syndrome: an overview. Am J Med Genet 117C 42-48
29. KW Gripp (2005) Tumor predisposition in Costello syndrome. Am J Med Genet C Semin Med Genet 137 72-77
30. Y Aoki, T Niihori, H Kawame, et al. (2005) Germline mutations in HRAS proto-oncogene cause Costello syndrome. Nat Genet 37 1038-1040
31. AL Estep, WE Tidyman, MA Teitell, et al. (2006) Hras mutations in Costello syndrome: detection of constitutional activating mutations in codon 12 and 13 and loss of wild-type allele in malignancy. Am J Med Genet A 140 8-16
32. S Schubbert, G Bollag and K Shannon (2007) Deregulated ras signaling in developmental disorders: new tricks for an old dog. Curr Opin Genet Dev 17 15-22
33. S Khan, H McDowell, M Upadhyaya and A Fryer (1995) Vaginal rhabdomyosarcoma in a patient with Noonan syndrome. J Med Genet 32 743-745
34. A Jung, S Bechthold, T Pfluger, et al. (2003) Orbital rhabdomyosarcoma in Noonan syndrome. J Pediatr Hematol Oncol 25 330-332
35. M Moschovi, T Vassiliki, P Anna, et al. (2007) Rhabdomyosarcoma in a patient with Noonan syndrome phenotype and review of the literature. J Pediatr Hematol Oncol 29 341-344
36. G Bisogno, A Murgia, I Mammi, et al. (1999) Rhabdomyosarcoma in a patient with cardio-fascio-cutaneous syndrome. J Pediatr Hematol Oncol 21 424-427
37. AM Innes and AE Chudley (2000) Rhabdomyosarcoma in a patient with cardio-fascio-cutaneous syndrome. J Pediatr Hematol Oncol 22 546-547
38. PI Agras, E Baskin, AE Sakallioglu, et al. (2003) Neurofibromatosis: Noonan's syndrome with associated rhabdomyosarcoma of the urinary bladder in an infant: case report. J Child Neurol 18 68-72
39. S Oguzkan, YK Terzi, E Guler, et al. (2006) Two neurofibromatosis type 1 cases associated with rhabdomyosarcoma of bladder, one with a large deletion in the NF1 gene. Cancer Genet Cytogenet 164 159-163
40. R Weksberg, C Shuman and AC Smith (2005) Beckwith-Wiedemann syndrome. Am J Med Genet C Semin Med Genet 137 12-23
41. UO Aideyan and SC Kao (1998) Case report: urinary bladder rhabdomyosarcoma associated with Beckwith-Wiedemann syndrome. Clin Radiol 53 457-459
42. C Sotelo-Avila, F Gonzalez-Crussi and JW Fowler (1980) Complete and incomplete forms of Beckwith-Wiedemann syndrome: their oncogenic potential. J Pediatr 96 47-50
43. WG Vaughan, DW Sanders, JL Grosfeld, et al. (1995) Favorable outcome in children with Beckwith-Wiedemann syndrome and intraabdominal malignant tumors. J Pediatr Surg 30 1042-1044
44. T Matsumoto, E Kinoshita, H Maeda, et al. (1994) Molecular analysis of a patient with Beckwith-Wiedemann syndrome, rhabdomyosarcoma and renal cell carcinoma. Jpn J Hum Genet 39 225-234
45. LL Rethy, RR Kalmanchey, VV Klujber, et al. (2000) Acid sphingomyelinase deficiency in Beckwith-Wiedemann syndrome. Pathol Oncol Res 6 295-297
46. AC Smith, JA Squire, P Thorner, et al. (2001) Association of alveolar rhabdomyosarcoma with the Beckwith-Wiedemann syndrome. Pediatr Dev Pathol 4 550-558
47. FB Ruymann, HR Maddux, A Ragab, et al. (1988) Congenital anomalies associated with rhabdomyosarcoma: an autopsy study of 115 cases. A report from the Intergroup Rhabdomyosarcoma Study Committee (representing the Children's Cancer Study Group, the Pediatric Oncology Group, the United Kingdom Children's Cancer Study Group, and the Pediatric Intergroup Statistical Center). Med Pediatr Oncol 16 33-39
48. DP Samuel, M Tsokos and MR DeBaun (1999) Hemihypertrophy and a poorly differentiated embryonal rhabdomyosarcoma of the pelvis. Med Pediatr Oncol 32 38-43
49. V Thavaraj, A Sethi and LS Arya (2002) Incomplete Beckwith-Wiedemann syndrome in a child with orbital rhabdomyosarcoma. Indian Pediatr 39 299-304
50. RL Johnson, AL Rothman, J Xie, et al. (1996) Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science 272 1668-1671
51. RJ Gorlin (1995) Nevoid basal cell carcinoma syndrome. Dermatol Clin 13 113-125
52. IR Beddis, MG Mott and J Bullimore (1983) Case report: nasopharyngeal rhabdomyosarcoma and Gorlin's naevoid basal cell carcinoma syndrome. Med Pediatr Oncol 11 178-179
53. CA Antley, M Carney and BR Smoller (1999) Microcystic adnexal carcinoma arising in the setting of previous radiation therapy. J Cutan Pathol 26 48-50
54. O Schweisguth, R Gerard-Marchant and J Lemerle (1968) Basal cell nevus syndrome: association with congenital rhabdomyosarcoma. Arch Fr Pediatr 25 1083-1093. (in French)
55. MM Cajaiba, AE Bale, M Alvarez-Franco, et al. (2006) Rhabdomyosarcoma, Wilms’ tumor, and deletion of the patched gene in Gorlin syndrome. Nat Clin Pract Oncol 3 575-580
56. JH Rubinstein and H Taybi (1963) Broad thumbs and toes and facial abnormalities: a possible mental retardation syndrome. Am J Dis Child 105 588-608
57. RW Miller and JH Rubinstein (1995) Tumors in Rubinstein-Taybi syndrome. Am J Med Genet 56 112-115. (comments)
58. PA Siraganian, JH Rubinstein and RW Miller (1989) Keloids and neoplasms in the Rubinstein-Taybi syndrome. Med Pediatr Oncol 17 485-491
59. RA Sobel and S Woerner (1981) Rubinstein-Taybi syndrome and nasopharyngeal rhabdomyosarcoma. J Pediatr 99 1000-1001. (letter)
60. K Imaizumi and Y Kuroki (1991) Rubinstein-Taybi syndrome with de novo reciprocal translocation t(2;16)(p13.3;p13.3). Am J Med Genet 38 636-639
61. F Petrij, RH Giles, HG Dauwerse, et al. (1995) Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP. Nature 376 348-351. (comments)
62. NH Tommerup, CB van der Hagen and A Heiberg (1992) Tentative assignment of a locus for Rubinstein-Taybi syndrome gene to 16p13.3 by a de novo reciprocal translocation, t(7;16)(q34;p13.3). Am J Med Genet Genet 44 237-241
63. NG Iyer, H Ozdag and C Caldas (2004) p300/ CBP and cancer. Oncogene 23 4225-4231
64. SR Grossman (2001) p300/ CBP/p53 interaction and regulation of the p53 response. Eur J Biochem 268 2773-2778
65. C Turc-Carel, S Lizard-Nacol, E Justrabo, et al. (1986) Consistent chromosomal translocation in alveolar rhabdomyosarcoma. Cancer Genet Cytogenet 19 361-362
66. EC Douglass, M Valentine, E Etcubanas, et al. (1987) A specific chromosomal abnormality in rhabdomyosarcoma. Cytogenet Cell Genet 45 148-155
67. S Wang-Wuu, S Soukup, E Ballard, et al. (1988) Chromosomal analysis of sixteen human rhabdomyosarcomas. Cancer Res 48 983-987
68. JA Biegel, RS Meek, AH Parmiter, et al. (1991) Chromosomal translocation t(1;13)(p36;q14) in a case of rhabdomyosarcoma. Genes Chromosomes Cancer 3 483-484
69. EC Douglass, ST Rowe, M Valentine, et al. (1991) Variant translocations of chromosome 13 in alveolar rhabdomyosarcoma. Genes Chromosomes Cancer 3 480-482
70. K Mrozek, DC Arthur, CP Karakousis, et al. (1995) Der(16)t(1;16) is a nonrandom secondary chromosome aberration in many types of human neoplasia, including myxoid liposarcoma, rhabdomyosarcoma and Philadelphia chromosome-positive acute lymphoblastic leukemia. Int J Oncol 6 531-538
71. AM Udayakumar, TS Sundareshan, L Appaji, et al. (2002) Rhabdomyosarcoma: cytogenetics of five cases using fine-needle aspiration samples and review of the literature. Ann Genet 45 33-37
72. S Weber-Hall, J Anderson, A McManus, et al. (1996) Gains, losses, and amplification of genomic material in rhabdomyosarcoma analyzed by comparative genomic hybridization. Cancer Res 56 3220-3224
73. A Pandita, M Zielenska, P Thorner, et al. (1999) Application of comparative genomic hybridization, spectral karyotyping, and microarray analysis in the identification of subtype-specific patterns of genomic changes in rhabdomyosarcoma. Neoplasia 1 262-275
74. JA Bridge, J Liu, SJ Qualman, et al. (2002) Genomic gains and losses are similar in genetic and histologic subsets of rhabdomyosarcoma, whereas amplification predominates in embryonal with anaplasia and alveolar subtypes. Genes Chromosomes Cancer 33 310-321
75. AT Gordon, C Brinkschmidt, J Anderson, et al. (2000) A novel and consistent amplicon at 13q31 associated with alveolar rhabdomyosarcoma. Genes Chromosomes Cancer 28 220-226
76. FG Barr, N Galili, J Holick, et al. (1993) Rearrangement of the PAX3 paired box gene in the paediatric solid tumour alveolar rhabdomyosarcoma. Nat Genet 3 113-117
77. RJ Davis, CM D’Cruz, MA Lovell, et al. (1994) Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma. Cancer Res 54 2869-2872
78. N Galili, RJ Davis, WJ Fredericks, et al. (1993) Fusion of a forkhead domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma (published erratum appears in Nat Genet 1994;6:214). Nat Genet 5 230-235
79. JL Bennicelli, S Advani, BW Schafer and FG Barr (1999) PAX3 and PAX7 exhibit conserved cis-acting transcription repression domains and utilize a common gain of function mechanism in alveolar rhabdomyosarcoma. Oncogene 18 4348-4356
80. JL Bennicelli, RH Edwards and FG Barr (1996) Mechanism for transcriptional gain of function resulting from chromosomal translocation in alveolar rhabdomyosarcoma. Proc Natl Acad Sci U S A 93 5455-5459
81. M Visser, C Sijmons, J Bras, et al. (1997) Allelotype of pediatric rhabdomyosarcoma. Oncogene 15 1309-1314
82. A Koufos, MF Hansen, NG Copeland, et al. (1985) Loss of heterozygosity in three embryonal tumours suggests a common pathogenetic mechanism. Nature 316 330-334
83. HJ Scrable, DP Witte, BC Lampkin and WK Cavenee (1987) Chromosomal localization of the human rhabdomyosarcoma locus by mitotic recombination mapping. Nature 329 645-647
84. C Brinkschmidt, C Poremba, KL Schafer, et al. (1998) Evidence of genetic alterations in chromosome 11 in embryonal and alveolar rhabdomyosarcoma. Verh Dtsch Ges Pathol 82 210-214. (in German)
85. WE Loh Jr, HJ Scrable, E Livanos, et al. (1992) Human chromosome 11 contains two different growth suppressor genes for embryonal rhabdomyosarcoma. Proc Natl Acad Sci U S A 89 1755-1759
86. M Koi, LA Johnson, LM Kalikin, et al. (1993) Tumor cell growth arrest caused by subchromosomal transferable DNA fragments from chromosome 11. Science 260 361-364
87. H Scrable, D Witte, H Shimada, et al. (1989) Molecular differential pathology of rhabdomyosarcoma. Genes Chromosomes Cancer 1 23-35
88. P Dias, P Kumar, HB Marsden, et al. (1990) The N- myc gene is amplified in alveolar rhabdomyosarcomas (RMS) but not in embryonal rms. Int J Cancer 45 593-596
89. D Driman, PS Thorner, ML Greenberg, et al. (1994) MYCN gene amplification in rhabdomyosarcoma. Cancer 73 2231-2237
90. Y Hachitanda, S Toyoshima and K Akazawa (1998) Tsuneyoshi M. N- myc gene amplification in rhabdomyosarcoma detected by fluorescence in situ hybridization: its correlation with histologic features. Mod Pathol 11 1222-1227
91. D Williamson, YJ Lu, T Gordon, et al. (2005) Relationship between MYCN copy number and expression in rhabdomyosarcomas and correlation with adverse prognosis in the alveolar subtype. J Clin Oncol 23 880-888
92. S Knuutila, AM Bjorkqvist, K Autio, et al. (1998) DNA copy number amplifications in human neoplasms: review of comparative genomic hybridization studies. Am J Pathol 152 1107-1123
93. JM Berner, A Forus, A Elkahloun, et al. (1996) Separate amplified regions encompassing CDK4 and MDM2 in human sarcomas. Genes Chromosomes Cancer 17 254-259
94. P Ragazzini, G Gamberi, L Pazzaglia, et al. (2004) Amplification of CDK4, MDM2, SAS and GLI1 genes in leiomyosarcoma, alveolar and embryonal rhabdomyosarcoma. Histol Histopathol 19 401-411
95. AC Taylor, L Shu, MK Danks, et al. (2000) p53 Mutation and MDM2 amplification frequency in pediatric rhabdomyosarcoma tumors and cell lines. Med Pediatr Oncol 35 96-103
96. Y Takahashi, Y Oda, K Kawaguchi, et al. (2004) Altered expression and molecular abnormalities of cell-cycle-regulatory proteins in rhabdomyosarcoma. Mod Pathol 17 660-669
97. FG Barr, LE Nauta, RJ Davis, et al. (1996) In vivo amplification of the PAX3-FKHR and PAX7-FKHR fusion genes in alveolar rhabdomyosarcoma. Hum Mol Genet 5 15-21
98. RJ Davis and FG Barr (1997) Fusion genes resulting from alternative chromosomal translocations are overexpressed by gene-specific mechanisms in alveolar rhabdomyosarcoma. Proc Natl Acad Sci U S A 94 8047-8051
99. D Williamson, J Selfe, T Gordon, et al. (2007) Role for amplification and expression of glypican-5 in rhabdomyosarcoma. Cancer Res 67 57-65
100. A De Chiara, A T’Ang and TJ Triche (1993) Expression of the retinoblastoma susceptibility gene in childhood rhabdomyosarcomas. J Natl Cancer Inst 85 152-157
101. A Iolascon, MF Faienza, B Coppola, et al. (1996) Analysis of cyclin-dependent kinase inhibitor genes (CDKN2A, CDKN2B, and CDKN2C) in childhood rhabdomyosarcoma. Genes Chromosomes Cancer 15 217-222
102. Z Gao, S Zhang and G Yang (1998) A study of p16 gene and its protein expression in rhabdomyosarcoma. Zhonghua Bing Li Xue Za Zhi 27 290-293
103. CA Felix, CC Kappel, T Mitsudomi, et al. (1992) Frequency and diversity of p53 mutations in childhood rhabdomyosarcoma. Cancer Res 52 2243-2247
104. MR Stratton, S Moss, W Warren, et al. (1990) Mutation of the p53 gene in human soft tissue sarcomas: association with abnormalities of the RB1 gene. Oncogene 5 1297-1301
105. P Wurl, H Taubert, M Bache, et al. (1996) Frequent occurrence of p53 mutations in rhabdomyosarcoma and leiomyosarcoma, but not in fibrosarcoma and malignant neural tumors. Int J Cancer 69 317-323
106. S Mousses, L McAuley, RS Bell, et al. (1996) Molecular and immunohistochemical identification of p53 alterations in bone and soft tissue sarcomas. Mod Pathol 9 1-6
107. T Kusafuka, M Fukuzawa, T Oue, et al. (1997) Mutation analysis of p53 gene in childhood malignant solid tumors. J Pediatr Surg 32 1175-1180
108. LM Mulligan, GJ Matlashewski, HJ Scrable and WK Cavenee (1990) Mechanisms of p53 loss in human sarcomas. Proc Natl Acad Sci U S A 87 5863-5867
109. MR Stratton, C Fisher, BA Gusterson and CS Cooper (1989) Detection of point mutations in n-ras and k-ras genes of human embryonal rhabdomyosarcomas using oligonucleotide probes and the polymerase chain reaction. Cancer Res 49 6324-6327
110. W Wilke, M Maillet and R Robinson (1993) H-ras-1 point mutations in soft tissue sarcomas. Mod Pathol 6 129-132
111. CP Kratz, D Steinemann, CM Niemeyer, et al. (2007) Uniparental disomy at chromosome 11p15.5 followed by HRAS mutations in embryonal rhabdomyosarcoma: lessons from Costello syndrome. Hum Mol Genet 16 374-379
112. Y Chen, J Takita, M Hiwatari, et al. (2006) Mutations of the PTPN11 and ras genes in rhabdomyosarcoma and pediatric hematological malignancies. Genes Chromosomes Cancer 45 583-591
113. J Miao, T Kusafuka and M Fukuzawa (2004) Hotspot mutations of BRAF gene are not associated with pediatric solid neoplasms. Oncol Rep 269-1272
114. C Seidel, F Bartel, M Rastetter, et al. (2005) Alterations of cancer-related genes in soft tissue sarcomas: hypermethylation of RASSF1a is frequently detected in leiomyosarcoma and associated with poor prognosis in sarcoma. Int J Cancer 114 442-447
115. G Schaaf, M Hamdi, D Zwijnenburg, et al. (2007) Spry1 functions as a collaborating oncogene in embryonal rhabdomyosarcoma cells expressing oncogenic ras or raf. Proc Annu Meet Am Assoc Cancer Res 48 5697
116. JG Herman and SB Baylin (2003) Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349 2042-2054
117. K Harada, S Toyooka, A Maitra, et al. (2002) Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines. Oncogene 21 4345-4349
118. K Harada, S Toyooka, N Shivapurkar, et al. (2002) Deregulation of caspase 8 and 10 expression in pediatric tumors and cell lines. Cancer Res 62 5897-5901
119. A Rathi, AK Virmani, K Harada, et al. (2003) Aberrant methylation of the hic1 promoter is a frequent event in specific pediatric neoplasms. Clin Cancer Res 9 3674-3678
120. H Shigematsu, M Suzuki, T Takahashi, et al. (2005) Aberrant methylation of hin-1 (high in normal-1) is a frequent event in many human malignancies. Int J Cancer 113 600-604
121. PN Tonin, H Scrable, H Shimada and WK Cavenee (1991) Muscle-specific gene expression in rhabdomyosarcomas and stages of human fetal skeletal muscle development. Cancer Res 51 5100-5106
122. NJ Sebire and M Malone (2003) Myogenin and myod1 expression in paediatric rhabdomyosarcomas. J Clin Pathol 56 412-416
123. RA Morotti, KK Nicol, DM Parham, et al. (2006) An immunohistochemical algorithm to facilitate diagnosis and subtyping of rhabdomyosarcoma: the Children's Oncology Group experience. Am J Surg Pathol 30 962-968
124. SJ Tapscott, MJ Thayer and H Weintraub (1993) Deficiency in rhabdomyosarcomas of a factor required for myod activity and myogenesis. Science 259 1450-1453
125. PL Puri, Z Wu, P Zhang, et al. (2000) Induction of terminal differentiation by constitutive activation of p38 map kinase in human rhabdomyosarcoma cells. Genes Dev 14 574-584
126. TA Fiddler, L Smith, SJ Tapscott and MJ Thayer (1996) Amplification of MDM2 inhibits myod-mediated myogenesis. Mol Cell Biol 16 5048-5057
127. CS Guo, C Degnin, TA Fiddler, et al. (2003) Regulation of myod activity and muscle cell differentiation by MDM2, prb, and Sp1. J Biol Chem 278 22615-22622
128. S Ricaud, B Vernus, M Duclos, et al. (2003) Inhibition of autocrine secretion of myostatin enhances terminal differentiation in human rhabdomyosarcoma cells. Oncogene 22 8221-8232
129. AN Gerber, CW Wilson, YJ Li and PT Chuang (2007) The hedgehog-regulated oncogenes gli1 and gli2 block myoblast differentiation by inhibiting myod-mediated transcriptional activation. Oncogene 26 1122-1136
130. MD Goulding, G Chalepakis, U Deutsch, et al. (1991) Pax-3, a novel murine DNA binding protein expressed during early neurogenesis. EMBO J 10 1135-1147
131. B Jostes, C Walther and P Gruss (1990) The murine paired box gene, Pax7, is expressed specifically during the development of the nervous and muscular system. Mech Dev 33 27-37
132. E Bober, T Franz, HH Arnold, et al. (1994) Pax-3 is required for the development of limb muscles: a possible role for the migration of dermomyotomal muscle progenitor cells. Development 120 603-612
133. P Seale, LA Sabourin, A Girgis-Gabardo, et al. (2000) Pax7 is required for the specification of myogenic satellite cells. Cell 102 777-786
134. F Relaix, D Montarras, S Zaffran, et al. (2006) Pax3 and Pax7 have distinct and overlapping functions in adult muscle progenitor cells. J Cell Biol 172 91-102
135. FG Barr (2001) Gene fusions involving fox and pax family members in alveolar rhabdomyosarcoma. Oncogene 20 5736-5746
136. N Tiffin, RD Williams, J Shipley and K Pritchard-Jones (2003) PAX7 expression in embryonal rhabdomyosarcoma suggests an origin in muscle satellite cells. Br J Cancer 89 327-332
137. M Maroto, R Reshef, AE Munsterberg, et al. (1997) Ectopic Pax-3 activates myod and myf-5 expression in embryonic mesoderm and neural tissue. Cell 89 139-148
138. J Khan, ML Bittner, LH Saal, et al. (1999) Cdna microarrays detect activation of a myogenic transcription program by the PAX3-FKHR fusion oncogene. Proc Natl Acad Sci U S A 96 13264-13269
139. C Scuoppo, I Riess, M Schmitt-Ney, et al. (2007) The oncogenic transcription factor PAX3-FKHR can convert fibroblasts into contractile myotubes. Exp Cell Res 313 2308-2317
140. JA Epstein, P Lam, L Jepeal, et al. (1995) Pax3 inhibits myogenic differentiation of cultured myoblast cells. J Biol Chem 270 11719-11722
141. M Ebauer, M Wachtel, FK Niggli and BW Schafer (2007) Comparative expression profiling identifies an in vivo target gene signature with tfap2b as a mediator of the survival function of PAX3/FKHR. Oncogene 26 7267-7281
142. CP Minniti and LJ Helman (1993) IGF- II in the pathogenesis of rhabdomyosarcoma: a prototype of IGF's involvement in human tumorigenesis. Adv Exp Med Biol 343 327-343
143. CP Minniti, D Luan, C O’Grady, et al. (1995) Insulin-like growth factor II overexpression in myoblasts induces phenotypic changes typical of the malignant phenotype. Cell Growth Differ 6 263-269
144. OM El-Badry, C Minniti, EC Kohn, et al. (1990) Insulin-like growth factor ii acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors. Cell Growth Differ 1 325-331
145. CP Minniti, EC Kohn, JH Grubb, et al. (1992) The insulin-like growth factor II (IGF-II)/mannose 6-phosphate receptor mediates IGF-II–induced motility in human rhabdomyosarcoma cells. J Biol Chem 267 9000-9004
146. T Kalebic, M Tsokos and LJ Helman (1994) In vivo treatment with antibody against igf-1 receptor suppresses growth of human rhabdomyosarcoma and down-regulates p34cdc2. Cancer Res 54 5531-5534
147. DN Shapiro, BG Jones, LH Shapiro, et al. (1994) Antisense-mediated reduction in insulin-like growth factor-I receptor expression suppresses the malignant phenotype of a human alveolar rhabdomyosarcoma. J Clin Invest 94 1235-1242
148. T Kalebic, V Blakesley, C Slade, et al. (1998) Expression of a kinase-deficient IGF-I-R suppresses tumorigenicity of rhabdomyosarcoma cells constitutively expressing a wild type IGF-I-R. Int J Cancer 76 223-227
149. PV Pedone, R Tirabosco, AO Cavazzana, et al. (1994) Mono- and bi-allelic expression of insulin-like growth factor ii gene in human muscle tumors. Hum Mol Genet 3 1117-1121
150. S Zhan, DN Shapiro and LJ Helman (1994) Activation of an imprinted allele of the insulin-like growth factor II gene implicated in rhabdomyosarcoma. J Clin Invest 94 445-448
151. J Anderson, A Gordon, A McManus, et al. (1999) Disruption of imprinted genes at chromosome region 11p15.5 in paediatric rhabdomyosarcoma. Neoplasia 1 340-348
152. KU Birkenkamp and PJ Coffer (2003) Regulation of cell survival and proliferation by the foxo (forkhead box, class o) subfamily of forkhead transcription factors. Biochem Soc Trans 31 292-297
153. L del Peso, VM Gonzalez, R Hernandez, et al. (1999) Regulation of the forkhead transcription factor fkhr, but not the PAX3-FKHR fusion protein, by the serine/threonine kinase AKT. Oncogene 18 7328-7333
154. S Scheidler, WJ Fredericks, F.J. Rauscher FJ 3rd, et al. (1996) The hybrid PAX3-FKHR fusion protein of alveolar rhabdomyosarcoma transforms fibroblasts in culture. Proc Natl Acad Sci U S A 93 9805-9809
155. PY Lam, JE Sublett, AD Hollenbach and MF Roussel (1999) The oncogenic potential of the PAX3-FKHR fusion protein requires the PAX3 homeodomain recognition helix but not the PAX3 paired-box DNA binding domain. Mol Cell Biol 19 594-601
156. WJ Fredericks, K Ayyanathan, M Herlyn, et al. (2000) An engineered PAX3-KRAB transcriptional repressor inhibits the malignant phenotype of alveolar rhabdomyosarcoma cells harboring the endogenous PAX3-FKHR oncogene. Mol Cell Biol 20 5019-5031
157. Y Cao and C Wang (2000) The cooh-terminal transactivation domain plays a key role in regulating the in vitro and in vivo function of Pax3 homeodomain. J Biol Chem 275 9854-9862
158. SJ Xia and FG Barr (2004) Analysis of the transforming and growth suppressive activities of the PAX3-FKHR oncoprotein. Oncogene 23 6864-6871
159. SJ Xia, P Rajput, DM Strzelecki and FG Barr (2007) Analysis of genetic events that modulate the oncogenic and growth suppressive activities of the PAX3-FKHR fusion oncoprotein. Lab Invest 87 318-325
160. CM Linardic, S Naini, J.E. Herndon JE 2nd, et al. (2007) The PAX3-FKHR fusion gene of rhabdomyosarcoma cooperates with loss of p16ink4a to promote bypass of cellular senescence. Cancer Res 67 6691-6699
161. M Bernasconi, A Remppis, WJ Fredericks, et al. (1996) Induction of apoptosis in rhabdomyosarcoma cells through down-regulation of PAX proteins. Proc Natl Acad Sci U S A 93 13164-13169
162. K Ayyanathan, WJ Fredericks, C Berking, et al. (2000) Hormone-dependent tumor regression in vivo by an inducible transcriptional repressor directed at the PAX3-FKHR oncogene. Cancer Res 60 5803-5814
163. T Kalebic, JG Judde, M Velez-Yanguas, et al. (1996) Metastatic human rhabdomyosarcoma: molecular, cellular and cytogenetic analysis of a novel cellular model. Invasion Metastasis 16 83-96
164. PL Lollini, C De Giovanni, L Landuzzi, et al. (1991) Reduced metastatic ability of in vitro differentiated human rhabdomyosarcoma cells. Invasion Metastasis 11 116-124
165. L Daniel, P Durbec, E Gautherot, et al. (2001) A nude mice model of human rhabdomyosarcoma lung metastases for evaluating the role of polysialic acids in the metastatic process. Oncogene 20 997-1004
166. BM Chan, N Matsuura, Y Takada, et al. (1991) In vitro and in vivo consequences of vla-2 expression on rhabdomyosarcoma cells. Science 251 1600-1602
167. F Diomedi-Camassei, R Boldrini, L Rava, et al. (2004) Different pattern of matrix metalloproteinase expression in alveolar versus embryonal rhabdomyosarcoma. J Pediatr Surg 39 1673-1679
168. M Onisto, ML Slongo, L Gregnanin, et al. (2005) Expression and activity of vascular endothelial growth factor and metalloproteinases in alveolar and embryonal rhabdomyosarcoma cell lines. Int J Oncol 27 791-798
169. FA Scholl, DR Betts, FK Niggli and BW Schafer (2000) Molecular features of a human rhabdomyosarcoma cell line with spontaneous metastatic progression. Br J Cancer 82 1239-1245
170. H Ito, M Duxbury, E Benoit, et al. (2004) Fibronectin-induced cox-2 mediates mmp-2 expression and invasiveness of rhabdomyosarcoma. Biochem Biophys Res Commun 318 594-600
171. J Libura, J Drukala, M Majka, et al. (2002) Cxcr4-sdf-1 signaling is active in rhabdomyosarcoma cells and regulates locomotion, chemotaxis, and adhesion. Blood 100 2597-2606
172. K Jankowski, M Kucia, M Wysoczynski, et al. (2003) Both hepatocyte growth factor (HGF) and stromal-derived factor-1 regulate the metastatic behavior of human rhabdomyosarcoma cells, but only HGF enhances their resistance to radiochemotherapy. Cancer Res 63 7926-7935
173. M Wysoczynski, K Miekus, K Jankowski, et al. (2007) Leukemia inhibitory factor: a newly identified metastatic factor in rhabdomyosarcomas. Cancer Res 67 2131-2140
174. R Sharp, JA Recio, C Jhappan, et al. (2002) Synergism between ink4a/arf inactivation and aberrant HGF/SF signaling in rhabdomyosarcomagenesis. Nat Med 8 1276-1280
175. Y Yu, J Khan, C Khanna, et al. (2004) Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastatic regulators. Nat Med 10 175-181
176. Y Yu, E Davicioni, TJ Triche and G Merlino (2006) The homeoprotein six1 transcriptionally activates multiple protumorigenic genes but requires ezrin to promote metastasis. Cancer Res 66 1982-1989
177. A Lavigueur, V Maltby, D Mock, et al. (1989) High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene. Mol Cell Biol 9 3982-3991
178. LA Donehower, M Harvey, BL Slagle, et al. (1992) Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356 215-221
179. T Jacks, L Remington, BO Williams, et al. (1994) Tumor spectrum analysis in p53-mutant mice. Curr Biol 4 1-7
180. P Nanni, G Nicoletti, C De Giovanni, et al. (2003) Development of rhabdomyosarcoma in HER- 2/neu transgenic p53 mutant mice. Cancer Res 63 2728-2732
181. A Fleischmann, W Jochum, R Eferl, et al. (2003) Rhabdomyosarcoma development in mice lacking Trp53 and Fos: tumor suppression by the Fos proto-oncogene. Cancer Cell 4 477-482
182. H Tsumura, T Yoshida, H Saito, et al. (2006) Cooperation of oncogenic k-ras and p53 deficiency in pleomorphic rhabdomyosarcoma development in adult mice. Oncogene 25 7673-7679
183. LV Goodrich, L Milenkovic, KM Higgins and MP Scott (1997) Altered neural cell fates and medulloblastoma in mouse patched mutants. Science 277 1109-1113
184. H Hahn, L Wojnowski, AM Zimmer, et al. (1998) Rhabdomyosarcomas and radiation hypersensitivity in a mouse model of Gorlin syndrome. Nat Med 4 619-622
185. C Wetmore, DE Eberhart and T Curran (2001) Loss of p53 but not arf accelerates medulloblastoma in mice heterozygous for patched. Cancer Res 61 513-516
186. R Kappler, R Bauer, J Calzada-Wack, et al. (2004) Profiling the molecular difference between patched- and p53-dependent rhabdomyosarcoma. Oncogene 23 8785-8795
187. M Koleva, R Kappler, M Vogler, et al. (2005) Pleiotropic effects of sonic hedgehog on muscle satellite cells. Cell Mol Life Sci 62 1863-1870
188. A Uhmann, U Ferch, R Bauer, et al. (2005) A model for ptch1/ptch1-associated tumors comprising mutational inactivation and gene silencing. Int J Oncol 27 1567-1575
189. H Hahn, L Wojnowski, K Specht, et al. (2000) Patched target IgF2 is indispensable for the formation of medulloblastoma and rhabdomyosarcoma. J Biol Chem 275 28341-28344
190. Y Lee, R Kawagoe, K Sasai, et al. (2007) Loss of suppressor-of-fused function promotes tumorigenesis. Oncogene 26 6442-6447
191. J Mao, KL Ligon, EY Rakhlin, et al. (2006) A novel somatic mouse model to survey tumorigenic potential applied to the hedgehog pathway. Cancer Res 66 10171-10178
192. H Takayama, WJ LaRochelle, R Sharp, et al. (1997) Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. Proc Natl Acad Sci U S A 94 701-706
193. MJ Anderson, GD Shelton, WK Cavenee and KC Arden (2001) Embryonic expression of the tumor-associated Pax3-FKHR fusion protein interferes with the developmental functions of Pax3. Proc Natl Acad Sci U S A 98 1589-1594
194. I Lagutina, SJ Conway, J Sublett and GC Grosveld (2002) Pax3-FKHR knock-in mice show developmental aberrations but do not develop tumors. Mol Cell Biol 22 7204-7216
195. F Relaix, M Polimeni, D Rocancourt, et al. (2003) The transcriptional activator PAX3-FKHR rescues the defects of Pax3 mutant mice but induces a myogenic gain-of-function phenotype with ligand-independent activation of Met signaling in vivo. Genes Dev 17 2950-2965
196. C Keller, MS Hansen, CM Coffin and MR Capecchi (2004) Pax3-Fkhr interferes with embryonic Pax3 and Pax7 function: implications for alveolar rhabdomyosarcoma cell of origin. Genes Dev 18 2608-2613
197. C Keller, BR Arenkiel, CM Coffin, et al. (2004) Alveolar rhabdomyosarcomas in conditional Pax3-Fkhr mice: cooperativity of Ink4a/arf and Trp53 loss of function. Genes Dev 18 2614-2626
198. JS Chamberlain, J Metzger, M Reyes, et al. (2007) Dystrophin-deficient mdx mice display a reduced life span and are susceptible to spontaneous rhabdomyosarcoma. FASEB J 21 2195-2204
199. RL Galindo, JA Allport and EN Olson (2006) A drosophila model of the rhabdomyosarcoma initiator PAX7-FKHR. Proc Natl Acad Sci U S A 103 13439-13444
200. DM Langenau, MD Keefe, NY Storer, et al. (2007) Effects of ras on the genesis of embryonal rhabdomyosarcoma. Genes Dev 21 1382-1395
201. FG Barr, LE Nauta and JC Hollows (1998) Structural analysis of PAX3 genomic rearrangements in alveolar rhabdomyosarcoma. Cancer Genet Cytogenet 102 32-39
202. JC Fitzgerald, AM Scherr and FG Barr (2000) Structural analysis of PAX7 rearrangements in alveolar rhabdomyosarcoma. Cancer Genet Cytogenet 117 37-40
203. FG Barr, QB Xiong and K Kelly (1995) A consensus polymerase chain reaction-oligonucleotide hybridization approach for the detection of chromosomal translocations in pediatric bone and soft tissue sarcomas. Am J Clin Pathol 104 627-633
204. FG Barr, LM Smith, JC Lynch, et al. (2006) Examination of gene fusion status in archival samples of alveolar rhabdomyosarcoma entered on the Intergroup Rhabdomyosarcoma Study-III trial: a report from the Children's Oncology Group. J Mol Diagn 8 202-208
205. JA Biegel, LM Nycum, V Valentine, et al. (1995) Detection of the t(2;13)(q35;q14) and PAX3-FKHR fusion in alveolar rhabdomyosarcoma by fluorescence in situ hybridization. Genes Chromosomes Cancer 12 186-192
206. J Nishio, PA Althof, JM Bailey, et al. (2006) Use of a novel FISH assay on paraffin-embedded tissues as an adjunct to diagnosis of alveolar rhabdomyosarcoma. Lab Invest 86 547-556
207. FG Barr, J Chatten, CM D’Cruz, et al. (1995) Molecular assays for chromosomal translocations in the diagnosis of pediatric soft tissue sarcomas. JAMA 273 553-557
208. E de Alava, M Ladanyi, J Rosai and WL Gerald (1995) Detection of chimeric transcripts in desmoplastic small round cell tumor and related developmental tumors by reverse transcriptase polymerase chain reaction: a specific diagnostic assay. Am J Pathol 147 1584-1591
209. KC Arden, MJ Anderson, FG Finckenstein, et al. (1996) Detection of the t(2;13) chromosomal translocation in alveolar rhabdomyosarcoma using the reverse transcriptase-polymerase chain reaction. Genes Chromosomes Cancer 16 254-260
210. C Reichmuth, MA Markus, M Hillemanns, et al. (1996) The diagnostic potential of the chromosome translocation t(2;13) in rhabdomyosarcoma: a pcr study of fresh-frozen and paraffin-embedded tumour samples. J Pathol 180 50-57
211. E Frascella, L Toffolatti and A Rosolen (1998) Normal and rearranged PAX3 expression in human rhabdomyosarcoma. Cancer Genet Cytogenet 102 104-109
212. PH Sorensen, JC Lynch, SJ Qualman, et al. (2002) PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the Children's Oncology Group. J Clin Oncol 20 2672-2679
213. FG Barr, SJ Qualman, MH Macris, et al. (2002) Genetic heterogeneity in the alveolar rhabdomyosarcoma subset without typical gene fusions. Cancer Res 62 4704-4710
214. M Wachtel, M Dettling, E Koscielniak, et al. (2004) Gene expression signatures identify rhabdomyosarcoma subtypes and detect a novel t(2;2)(q35;p23) translocation fusing PAX3 to ncoa1. Cancer Res 64 5539-5545
215. R Grundy, J Anderson, M Gaze, et al. (2001) Congenital alveolar rhabdomyosarcoma: clinical and molecular distinction from alveolar rhabdomyosarcoma in older children. Cancer 91 606-612
216. DM Parham, SJ Qualman, L Teot, et al. (2007) Correlation between histology and PAX/FKHR fusion status in alveolar rhabdomyosarcoma: a report from the Children's Oncology Group. Am J Surg Pathol 31 895-901
217. KM Kelly, RB Womer, PH Sorensen, et al. (1997) Common and variant gene fusions predict distinct clinical phenotypes in rhabdomyosarcoma. J Clin Oncol 15 1831-1836
218. B Kazanowska, A Reich, S Stegmaier, et al. (2007) PAX3-FKHR and PAX7-FKHR fusion genes impact outcome of alveolar rhabdomyosarcoma in children. Fetal Pediatr Pathol 26 17-31
219. C De Pitta, L Tombolan, G Albiero, et al. (2006) Gene expression profiling identifies potential relevant genes in alveolar rhabdomyosarcoma pathogenesis and discriminates PAX3-FKHR positive and negative tumors. Int J Cancer 118 2772-2781
220. E Davicioni, FG Finckenstein, V Shahbazian, et al. (2006) Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas. Cancer Res 66 6936-6946
221. M Lae, EH Ahn, GE Mercado, et al. (2007) Global gene expression profiling of PAX-FKHR fusion-positive alveolar and PAX-FKHR fusion-negative embryonal rhabdomyosarcomas. J Pathol 212 143-151
222. B Molnar, F Sipos, O Galamb and Z Tulassay (2003) Molecular detection of circulating cancer cells: role in diagnosis, prognosis and follow-up of colon cancer patients. Dig Dis 21 320-325
223. MJ Slade and RC Coombes (2007) The clinical significance of disseminated tumor cells in breast cancer. Nat Clin Pract Oncol 4 30-41
224. TM Morgan, PH Lange and RL Vessella (2007) Detection and characterization of circulating and disseminated prostate cancer cells. Front Biosci 12 3000-3009
225. KM Kelly, RB Womer and FG Barr (1996) Minimal disease detection in patients with alveolar rhabdomyosarcoma using a reverse transcriptase-polymerase chain reaction method. Cancer 78 1320-1327
226. F Sartori, R Alaggio, G Zanazzo, et al. (2006) Results of a prospective minimal disseminated disease study in human rhabdomyosarcoma using three different molecular markers. Cancer 106 1766-1775
227. S Gallego, A Llort, J Roma, et al. (2006) Detection of bone marrow micrometastasis and microcirculating disease in rhabdomyosarcoma by a real-time RT-PCR assay. J Cancer Res Clin Oncol 132 356-362
228. HP McDowell, A Donfrancesco, GM Milano, et al. (2005) Detection and clinical significance of disseminated tumour cells at diagnosis in bone marrow of children with localised rhabdomyosarcoma. Eur J Cancer 41 2288-2296
229. J Gurney, J Young, S Roffers, et al. (1999) Cancer incidence and survival among children and adolescents: United States SEER program 1975-1995. L Ries, MA Smith, J Gurney, et al., (Eds) SEER pediatric monograph Bethesda, Md: National Cancer Institute, SEER Program 111-123
230. http://seer.cancer.gov/csr/1975_2003/results_merged/sect_29_childhood_cancer_iccc.pdf Accessed June 1, 2008
231. ML Klem, RK Grewal, LH Wexler, et al. (2007) PET for staging in rhabdomyosarcoma: an evaluation of PET as an adjunct to current staging tools. J Pediatr Hematol Oncol 29 9-14
232. T Volker, T Denecke, I Steffen, et al. (2007) Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial. J Clin Oncol 25 5435-5441
233. A Mazumdar, M Siegel, V Narra and L Lichtman-Jones (2002) Whole-body fast inversion recovery MR imaging of small cell neoplasms in pediatric patients. AJR Am J Roentgenol 179 1261-1266
234. HE Daldrup-Link, C Franzius, TM Link, et al. (2001) Whole-body MR imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG pet. AJR Am J Roentgenol 177 229-236
235. D Joshi, JR Anderson, C Paidas, et al. (2004) Age is an independent prognostic factor in rhabdomyosarcoma: a report from the soft tissue sarcoma committee of the Children's Oncology Group. Pediatr Blood Cancer 42 64-73
236. C Rodary, EA Gehan, F Flamant, et al. (1991) Prognostic factors in 951 nonmetastatic rhabdomyosarcoma in children: a report from the International Rhabdomyosarcoma Workshop. Med Pediatr Oncol 19 89-95
237. J Meza, J Anderson, AS Pappo and WH Meyer (2006) Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on Intergroup Rhabdomyosarcoma Studies III and IV: The Children's Oncology Group. J Clin Oncol 24 3844-3852
238. J Lager, E Lyden, JR Anderson, et al. (2006) Pooled analysis of phase II window studies in children with contemporary high-risk metastatic rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol 24 3415-3422
239. H Maurer, M Beltangady, E Gehan, et al. (1988) The Intergroup Rhabdomyosarcoma Study-I: a final report. Cancer 61 209-220
240. HM Maurer, EA Gehan, M Beltangady, et al. (1993) The Intergroup Rhabdomyosarcoma Study-II. Cancer 71 1904-1922
241. E Koscielniak, D Harms, G Henze, et al. (1999) Results of treatment for soft tissue sarcoma in childhood and adolescence: a final report of the German Cooperative Soft Tissue Sarcoma Study CWS-86. J Clin Oncol 17 3706-3719
242. RB Raney, JR Anderson, FG Barr, et al. (2001) Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of Intergroup Rhabdomyosarcoma Study group experience and rationale for Intergroup Rhabdomyosarcoma Study-V. J Pediatr Hematol Oncol 23 215-220
243. JC Breneman, E Lyden, AS Pappo, et al. (2003) Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study-IV. J Clin Oncol 21 78-84
244. TM Dantonello, C Int-Veen, P Winkler, et al. (2008) Initial patient characteristics can predict pattern and risk of relapse in localized rhabdomyosarcoma. J Clin Oncol 26 406-413
245. RM Heyn, R Holland, WA Newton, et al. (1974) The role of combined chemotherapy in the treatment of rhabdomyosarcoma in children. Cancer 34 2128-2142
246. C Pratt, H Hustu, I Fleming and D Pinkel (1972) Coordinated treatment of childhood rhabdomyosarcoma with surgery, radiotherapy, and combination chemotherapy. Cancer Res 32 606-610
247. T Haddy, A Nora, W Sutow and T Vietti (1967) Cyclophosphamide treatment for metastatic soft tissue sarcoma. Am J Dis Child 114 301-308
248. RB Womer (1993) The Intergroup Rhabdomyosarcoma Studies come of age. Cancer 71 1719-1721
249. W Crist, EA Gehan, AH Ragab, et al. (1995) The third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 13 610-630
250. WM Crist, JR Anderson, JL Meza, et al. (2001) Intergroup Rhabdomyosarcoma Study-IV: results for patients with nonmetastatic disease. J Clin Oncol 19 3091-3102
251. SL Spunt, LM Smith, FB Ruymann, et al. (2004) Cyclophosphamide dose intensification during induction therapy for intermediate-risk pediatric rhabdomyosarcoma is feasible but does not improve outcome: a report from the soft tissue sarcoma committee of the Children's Oncology Group. Clin Cancer Res 10 6072-6079
252. F Flamant, C Rodary, A Rey, et al. (1998) Treatment of non-metastatic rhabdomyosarcomas in childhood and adolescence: results of the second study of the International Society of Paediatric Oncology: Mmt-84. Eur J Cancer 34 1050-1062
253. M Stevens, A Rey, N Bouvet, et al. (2004) Intensified (6-drug) versus standard (IVA) chemotherapy for high-risk non metastatic rhabdomyosarcoma (RMS). J Clin Oncol 22 802. (abstract)
254. J de Kraker and PA Voute (1986) The role of ifosfamide in paediatric soft tissue sarcomas. Cancer Chemother Pharmacol 18(suppl 2), S23-S24
255. PJ Shaw and T Eden (1990) Ifosfamide in paediatric oncology: tried but not tested? Lancet 335 1022-1023
256. RB Womer (1996) Ifosfamide and paediatrics: should this marriage be saved? Eur J Cancer 32A 1100-1101
257. F Kung, FA Hayes, J Krischer, et al. (1988) Clinical trial of etoposide (VP-16) in children with recurrent malignant solid tumors. A phase II study from the Pediatric Oncology Group. Investigational New Drugs 6 31-36
258. JS Miser, TJ Kinsella, TJ Triche, et al. (1987) Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol 5 1191-1198
259. A Davidson, R Growing, S Lowis, et al. (1997) Phase II study of 21-day-schedule of oral etoposide in children. Eur J Cancer 33 1816-1822
260. R Kebudi, O Gorgun and I Ayan (2004) Oral etoposide for recurrent/progressive sarcomas of childhood. Pediatr Blood Cancer 42 320-324
261. RL Saylors, SC Stine, J Sullivan, et al. (2001) Cyclophosphamide plus topotecan in children with recurrent of refractory solid tumors: a Pediatric Oncology Group phase II study. J Clin Oncol 19 3463-3469
262. AS Pappo, E Lynden, J Breneman, et al. (2001) Up-front window trial of topotecan in previously untreated children and adolescents with metastatic rhabdomyosarcoma: an Intergroup Rhabdomyosarcoma Study. J Clin Oncol 19 213-219
263. D Walterhouse, E Lyden, P Breitfeld, et al. (2004) Efficacy of topotecan and cyclophosphamide given in a phase II window trial in children with newly diagnosed metastatic rhabdomyosarcoma: a Children's Oncology Group study. J Clin Oncol 22 1398-1403
264. C Arndt, D Hawkins, J Stoner, et al. (2007) Randomized phase III trial comparing vincristine, actinomycin, cyclophosphamide (VAC) with VAC/v topotecan/cyclophosphamide (tc) for intermediate-risk rhabdomyosarcoma (IRRMS). D9803, COG study. J Clin Oncol 25(18 Suppl),
265. PJ Houghton and VM Santana (2002) Clinical trials using irinotecan. J Pediatr Hematol Oncol 24 84-85. (comment)
266. G Vassal, D Couanet, E Stockdale, et al. (2007) Phase II trial of irinotecan in children with relapsed or refractory rhabdomyosarcoma: a joint study of the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group. J Clin Oncol 25 356-361
267. LR Bomgaars, M Bernstein, M Krailo, et al. (2007) Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group study. J Clin Oncol 25 4622-4627
268. WL Furman, CF Stewart, CA Poquette, et al. (1999) Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. J Clin Oncol 17 1815-1824
269. G Bisogno, R Riccardi, A Ruggiero, et al. (2006) Phase II study of a protracted irinotecan schedule in children with refractory or recurrent soft tissue sarcoma. Cancer 106 703-707
270. J Thompson, EO George, CA Poquette, et al. (1999) Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts. Clin Cancer Res 5 3617-3631
271. AS Pappo, E Lyden, P Breitfeld, et al. (2007) Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group. J Clin Oncol 25 362-369
272. L Mascarenhas, E Lyden, P Breitfeld, et al. (2008) Randomized phase II window study of two schedules of irinotecan (CPT-II) and vincristine (VCR) in rhabdomyosarcoma at first relapse/disease progression. J Clin Oncol 26 10013
273. M Carli, G Perilongo, LC di Montezemolo, et al. (1987) Phase II trial of cisplatin and etoposide in children with advanced soft tissue sarcoma: a report from the Italian Cooperative Rhabdomyosarcoma Group. Cancer Treat Rep 71 525-527
274. P Van Winkle, A Angiolillo, M Krailo, et al. (2005) Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children's Cancer Group (CCG) experience. Pediatr Blood Cancer 44 338-347
275. JC Chisholm, D Machin, H McDowell, et al. (2007) Efficacy of carboplatin given in a phase II window study to children and adolescents with newly diagnosed metastatic soft tissue sarcoma. Eur J Cancer 43 2537-2544
276. PP Breitfeld, E Lyden, RB Raney, et al. (2001) Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study group. Pediatr Hematol Oncol 23 225-233
277. CA Arndt, DS Hawkins, WH Meyer, et al. (2008) Comparison of results of a pilot study of alternating vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide with IRS-IV in intermediate-risk rhabdomyosarcoma: a report from the Children's Oncology Group. Pediatr Blood Cancer 50 33-36
278. F Flamant, C Rodary, A Rey, et al. (1998) Treatment of non-metastatic rhabdomyosarcoma in childhood and adolescence: results of the second study of the International Society of Paediatric Oncology: MMT84. Eur J Cancer 34 1050-1062
279. O Oberlin, A Rey, J Anderson, et al. (2001) Treatment of orbital rhabdomyosarcoma: survival and late effects of treatment: results of an international workshop. J Clin Oncol 19 197-204
280. SS Donaldson and JR Anderson (2005) Rhabdomyosarcoma: many similarities, a few philosophical differences. J Clin Oncol 23 2586-2587. (comment)
281. F Peng, G Rabkin and O Muzik (2006) Use of 2-deoxy-2-[f-18]-fluoro-d-glucose positron emission tomography to monitor therapeutic response by rhabdomyosarcoma in children: report of a retrospective case study. Clin Nucl Med 31 394-397
282. DM Hays, W Lawrence Jr, M Wharam, et al. (1989) Primary reexcision for patients with microscopic residual tumor following initial excision of sarcomas of trunk and extremity sites. J Pediatr Surg 24 5-10
283. ES Wiener, JR Anderson, JI Ojimba, et al. (2001) Controversies in the management of paratesticular rhabdomyosarcoma: is staging retroperitoneal lymph node dissection necessary for adolescents with resected paratesticular rhabdomyosarcoma? Semin Pediatr Surg 10 146-152
284. JC Breneman and ES Wiener (2000) Issues in the local control of rhabdomyosarcoma. Med Pediatr Oncol 35 104-109
285. ML Blakely, TE Lobe, JR Anderson, et al. (1999) Does debulking improve survival rate in advanced-stage retroperitoneal embryonal rhabdomyosarcoma? J Pediatr Surg 34 736-742
286. G Cecchetto, G Bisogno, F De Corti, et al. (2007) Biopsy or debulking surgery as initial surgery for locally advanced rhabdomyosarcomas in children?: the experience of the Italian Cooperative Group studies. Cancer 110 2561-2567
287. A Viswanathan, H Grier, H Litman, et al. (2004) Outcome for children with group III rhabdomyosarcoma treated with or without radiotherapy. Int J Radiation Oncology Biol Phys 58 1208-1214
288. SL Wolden, JR Anderson, WM Crist, et al. (1999) Indications for radiotherapy and chemotherapy after complete resection in rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Studies I to III. J Clin Oncol 17 3468-3475
289. A Schuck, AC Mattke, B Schmidt, et al. (2004) Group II rhabdomyosarcoma and rhabdomyosarcoma-like tumors: is radiotherapy necessary? J Clin Oncol 22 143-149
290. LM Smith, JR Snderosn, SJ Qualman, et al. (2001) Which patients with microscopic disease and rhabdomyosarcoma experience relapse after therapy? A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol 19 4058-4064
291. MCG Stevens, A Rey, N Bouvet, et al. (2005) Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology: SIOP malignant mesenchymal tumor 89. J Clin Oncol 23 2618-2628
292. L Mandell, F Ghavimi, T Peretz, et al. (1990) Radiocurability of microscopic disease in childhood rhabdomyosarcoma with radiation doses less than 4,000 cGy. J Clin Oncol 8 1536-1542
293. S Nag, T Olson, F Ruymann, et al. (1995) High-dose-rate brachytherapy in childhood sarcomas: a local control strategy preserving bone growth and function. Med Pediatr Oncol 25 463-469
294. S Nag, R Martinez-Monge, F Ruymann, et al. (1997) Innovation in the management of soft tissue sarcomas in infants and young children: high-dose rate brachytherapy. J Clin Oncol 15 3075-3084
295. J Buwalda, P Schouwenburg, L Blank, et al. (2003) A novel local treatment strategy for advanced-stage head and neck rhabdomyosarcomas in children: results of the Amore Protocol. Eur J Cancer 39 1594-1602
296. TE Merchant, MJ Zelefsky, JM Sheldon, et al. (1998) High-dose rate intraoperative radiation therapy for pediatric solid tumors. Med Pediatr Oncol 30 34-39
297. AM Gillis, E Sutton, KD Dewitt, et al. (2007) Long-term outcome and toxicities of intraoperative radiotherapy for high-risk neuroblastoma. Int J Radiat Oncol Biol Phys 69 858-864
298. PJ Schomberg, LL Gunderson, CR Moir, et al. (1997) Intraoperative electron irradiation in the management of pediatric malignancies. Cancer 79 2251-2256
299. JA Kalapurakal, S Goldman, W Stellpflug, et al. (2006) Phase I study of intraoperative radiotherapy with photon radiosurgery system in children with recurrent brain tumors: preliminary report of first dose level (10 Gy). Int J Radiat Oncol Biol Phys 65 800-808
300. GM Haase, DP Meagher Jr, LK McNeely, et al. (1994) Electron beam intraoperative radiation therapy for pediatric neoplasms. Cancer 74 740-747
301. R Miralbell, A Lomax, L Cella and U Schneider (2002) Potential reduction of the incidence of radiation-induced second cancers by using proton beams in the treatment of pediatric tumors. Int J Radiat Oncol Biol Phys 54 824-829
302. T Yock, R Schneider, A Friedmann, et al. (2005) Proton radiotherapy for orbital rhabdomyosarcoma: clinical outcome and a dosimetric comparison with photons. Int J Radiat Oncol Biol Phys 63 1161-1168
303. B Timmermann, A Schuck, F Niggli, et al. (2007) Spot-scanning proton therapy for malignant soft tissue tumors in childhood: first experiences at the Paul Scherrer Institute. Int J Radiat Oncol Biol Phys 67 497-504
304. C Arndt, D Hawkins, J Anderson, et al. (2004) Age is a risk factor for chemotherapy-induced hepatopathy with vincristine, dactinomycin, and cyclophosphamide. J Clin Oncol 22 1894-1901
305. D Orbach, A Rey, O Oberlin, et al. (2005) Soft tissue sarcoma or malignant mesenchymal tumors in the first year of life: experience of the International Society of Pediatric Oncology (SIOP) malignant mesenchymal tumor committee. J Clin Oncol 23 4363-4371
306. RB Raney, E Gehan, DM Hays, et al. (1990) Primary chemotherapy with or without radiation therapy and/or surgery for children with localized sarcoma of the bladder, prostate, vagina, uterus, and cervix: a comparison of the results in Intergroup Rhabdomyosarcoma Studies I and II. Cancer 66 2072-2081
307. T Lobe, E Wiener, R Andrassy, et al. (1996) The argument for conservative, delayed surgery in the management of prostatic rhabdomyosarcoma. J Pediatr Surg 31 1084-1087
308. C Arndt, D Rodeberg, PP Breitfeld, et al. (2004) Does bladder preservation (as a surgical principle) lead to retaining bladder function in bladder/prostate rhabdomyosarcoma? Results from Intergroup Rhabdomyosarcoma Study IV. J Urol 171 2396-2403. (comment)
309. RB Raney, R Heyn, DM Hays, et al. (1993) Sequelae of treatment in 109 patients followed 5 to 15 years after diagnosis of sarcoma of the bladder and prostate. Cancer 71 2387-2394
310. SL Spunt, TA Sweeney, MM Hudson, et al. (2005) Late effects of pelvic rhabdomyosarcoma and its treatment in female survivors. J Clin Oncol 23 7143-7151
311. C Yeung, H Ward, P Ransley, et al. (1994) Bladder and kidney function after cure of pelvic rhabdomyosarcoma in childhood. Br J Cancer 70 1000-1003
312. RB Womer and HM Snyder (2006) Bladder/prostate rhabdomyosarcoma: miles to go before we sleep. J Urol 176 1278-1279. (comment)
313. CA Arndt, S Hammond, D Rodeberg and S Qualman (2006) Significance of persistent mature rhabdomyoblasts in bladder/prostate rhabdomyosarcoma: results from IRS IV. J Pediatr Hematol Oncol 28 563-567
314. E Koscielniak, H Jurgens, K Winkler, et al. (1992) Treatment of soft tissue sarcoma in childhood and adolescence: a report of the German Cooperative Soft tissue Sarcoma study. Cancer 70 2557-2567
315. RB Raney, J Meza, JR Anderson, et al. (2002) Treatment of children and adolescents with localized parameningeal sarcoma: experience of the Intergroup Rhabdomyosarcoma Study group protocols IRS-II through -IV, 1978-1997. Med Pediatr Oncol 38 22-32
316. B Raney, M Tefft, R Heyn, et al. (1992) Ascending myelitis after intensive chemotherapy and radiation therapy in children with cranial parameningeal sarcoma. Cancer 69 1498-1506
317. V Benk, C Rodary, SS Donaldson, et al. (1996) Parameningeal rhabdomyosarcoma: results of an international workshop. Int J Radiat Oncol Biol Phys 36 533-540
318. JM Michalski, J Meza, JC Breneman, et al. (2004) Influence of radiation therapy parameters on outcome in children treated with radiation therapy for localized parameningeal rhabdomyosarcoma in Intergroup Rhabdomyosarcoma Study group trials II through IV. Int J Radiat Oncol Biol Phys 59 1027-1038
319. C Chen, HK Shu, JW Goldwein, et al. (2003) Volumetric considerations in radiotherapy for pediatric parameningeal rhabdomyosarcomas. Int J Radiat Oncol Biol Phys 55 1294-1299
320. SC Smith, SK Lindsley, J Felgenhauer, et al. (2003) Intensive induction chemotherapy and delayed irradiation in the management of parameningeal rhabdomyosarcoma. J Pediatr Hematol Oncol 25 774-779
321. A Pappo, J Anderson, W Crist, et al. (1999) Survival after relapse in children and adolescents with rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study group. J Clin Oncol 17 3487-3493
322. PA Meyers (2004) High-dose therapy with autologous stem cell rescue for pediatric sarcomas. Curr Opin Oncol 16 120-125
323. MD Wharam, J Meza, J Anderson, et al. (2004) Failure pattern and factors predictive of local failure in rhabdomyosarcoma: a report of group III patients in the third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 22 1902-1908
324. R Skinner, IM Sharkey, AD Pearson and AW Craft (1993) Ifosfamide, mesna, and nephrotoxicity in children. J Clin Oncol 11 173-190. (review)